ImmuCell (NASDAQ:ICCC) Issues Earnings Results

by · The Cerbat Gem

ImmuCell (NASDAQ:ICCC – Get Free Report) announced its earnings results on Wednesday. The biotechnology company reported ($0.32) earnings per share for the quarter, FiscalAI reports. The business had revenue of $7.63 million for the quarter. ImmuCell had a negative net margin of 3.76% and a negative return on equity of 3.52%.

ImmuCell Price Performance

Shares of NASDAQ ICCC traded down $0.05 during mid-day trading on Friday, reaching $6.30. The company had a trading volume of 722 shares, compared to its average volume of 19,018. The company has a current ratio of 4.21, a quick ratio of 1.76 and a debt-to-equity ratio of 0.27. ImmuCell has a 1-year low of $4.28 and a 1-year high of $7.60. The stock has a market cap of $57.02 million, a PE ratio of -57.27 and a beta of 0.27. The company has a 50-day moving average price of $6.38 and a two-hundred day moving average price of $6.09.

Institutional Trading of ImmuCell

Several hedge funds and other institutional investors have recently modified their holdings of ICCC. Geode Capital Management LLC grew its position in ImmuCell by 4.2% in the second quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock worth $500,000 after acquiring an additional 2,907 shares in the last quarter. Mesirow Financial Investment Management Inc. increased its stake in shares of ImmuCell by 199.6% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock worth $224,000 after purchasing an additional 24,303 shares during the period. Finally, Steadtrust LLC lifted its holdings in shares of ImmuCell by 79.1% during the fourth quarter. Steadtrust LLC now owns 56,770 shares of the biotechnology company’s stock worth $349,000 after buying an additional 25,070 shares during the last quarter. Institutional investors and hedge funds own 13.47% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of ImmuCell from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, February 24th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company currently has an average rating of “Hold”.

View Our Latest Report on ICCC

About ImmuCell

(Get Free Report)

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.

Recommended Stories